Serna MJA, Maldonado SA, Pablo SJ, Ramírez AJL, Luviano C

Language: Spanish
References: 21
Page: 235-242
PDF size: 127.97 Kb.

ABSTRACT

The fusion of positron emission tomography with 18-F flouordeoxyglucose, with computed tomography (FDG-PET/CT) is a diagnostic procedure which has been progressively incorporated to clinical practice around the world during the last decade. There are several indications in which FDG. PET/CT has demonstrated a better diagnostic accuracy when compared with conventional methods. In order to optimize the use of this new technique it is recommendable to select those cases where FDG- PET/CT has shown to be clearly better than the conventional techniques, as staging of lung cancer and lymphoma, thyroid, colorectal and head and neck cancer and melanoma, also useful in localization of unknown primary site carcinomas; diagnosis of solitary pulmonary nodules and differentiation of tumor recurrence from radionecrosis in brain tumors.

REFERENCES

1. Tomografía por emisión de positrones (PET) con 18FDG en oncología clínica (Revisión Sistemática). Informe de la Agencia de Evaluación de Tecnologías Sanitarias Nº 30. Instituto de Salud Carlos III. Ministerio de Sanidad y Consumo. Madrid, Noviembre de 2001.

2. Protocolo de uso tutelado para la recogida de información sobre la utilización de la 18FDG-PET. Informe de la Agencia de Evaluación de Tecnologías Sanitarias. Instituto de Salud Carlos III. Ministerio de Sanidad y Consumo. Madrid, Mayo de 2002.

3. Henze M, Mohammed A, Schlemmer HP, Herfarth KK, Hoffner S, Haufe S et al. PET and SPECT for detection of tumor progression in irradiated low-grade astrocytoma: A receiver-operating-characteristic analysis. J Nucl Med 2004; 45: 579-586.

4. Chao ST, Suh JH, Raja S, Lee SY, Barnett G. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 2001; 96: 191-197.

5. Gibson MK, Forastiere AA. Multidisciplinary approaches in the management of advanced head and neck tumors: state of the art. Curr Opin Oncol 2004; 16: 220-224.

6. Nowak B, Di Martino E, Janicke S, Cremerius U, Adam G, Zimny M et al. Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/MRI. Nuklearmedizin 1999; 38: 312-318.

7. Masahiro I, Kanji K, Takashi M, Keiichi M, Yasuhiro I, Takayoshi I et al. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer. Eur J Nucl Med Mol Imaging 2004; 31: 491-498.

8. Frilling A, Gorges R, Tecklenborg K, Gassmann P, Bockhorn M, Clausen M et al. Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma. Surgery 2000; 128: 1067-1074.

9. Plokkin et al. Thyroid 2002 ; 12: 155-161.

10. Kelly RF, Tran T, Holmstrom A, Murar J, Segurola RJ Jr. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer. Chest 2004; 125: 1413-1423.

11. Kelly RF, Tran T, Holmstrom A, Murar J, Segurola RJ Jr. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer. Chest 2004; 125: 1413-1423.

12. Fischer BM, Mortensen J, Dirksen A, Eigtved A, Hojgaard L. Positron emission tomography of incidentally detected small pulmonary nodules. Nucl Med Commun 2004; 25: 3-9.

13. Dewan NA, Shehan CJ, Reeb SD, Gobar LS, Scott WJ, Ryschon K. Likelihood of malignancy in a solitary pulmonary nodule: comparison of Bayesian analysis and results of FDG-PET scan. Chest 1997; 112: 416-422.

14. Ruers BS, Langenhoff N, Neeleman GJ, Jager S, Strijk Th, Wobbes F et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: A prospective study TJM. J Clin Oncol 2002; 20: 388-395.

15. Topal B, Flamen P, Aerts R, D’Hoore A, Filez L, Van Cutsem E et al. Clinical value of whole-body emission tomography in potentially curable colorectal liver metastases. Eur J Surg Oncol 2001; 27: 175-179.

16. Friedberg JW, Fischman A, Neuberg D, Kim H, Takvorian T, Ng A et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma 2004; 45: 85-92.

17. Filmont JE, Yap CS, Ko F, Vranjesevic D, Quon A, Margolis DJ et al. Conventional imaging and 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography for predicting the clinical outcome of patients with previously treated Hodgkin’s disease. Mol Imaging Biol 2004; 6: 47-54.

18. Jereczek-Fossa BA, Jassem J, Orecchia R. Cervical lymph node metastases of squamous cell carcinoma from an unknown primary. Cancer Treat Rev 2004; 30: 153-164.

19. Bohuslavizki KH, Klutmann S, Kroger S, Sonnemann U, Buchert R, Werner JA et al. FDG PET detection of unknown primary tumors. J Nucl Med 2000; 41: 816-822..

20. Fink AM, Holle-Robatsch S, Herzog N, Mirzaei S, Rappersberger K, Lilgenau N et al. Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II. Melanoma Res 2004; 14: 141-145.

21. Gulec SA, Faries MB, Lee CC, Kirgan D, Glass C, Morton DL et al. The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making. Clin Nucl Med 2003; 28: 961-965.